- Previous Close
0.6800 - Open
0.6890 - Bid 0.5264 x 200
- Ask 0.8594 x 200
- Day's Range
0.6611 - 0.7647 - 52 Week Range
0.6600 - 6.9800 - Volume
3,604,676 - Avg. Volume
2,308,696 - Market Cap (intraday)
86.28M - Beta (5Y Monthly) 2.41
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6400 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.25
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.fatetherapeutics.comRecent News: FATE
View More
Performance Overview: FATE
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FATE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FATE
View MoreValuation Measures
Market Cap
87.62M
Enterprise Value
-106.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.38
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.81%
Return on Equity (ttm)
-54.21%
Revenue (ttm)
13.63M
Net Income Avi to Common (ttm)
-186.26M
Diluted EPS (ttm)
-1.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
279.07M
Total Debt/Equity (mrq)
26.75%
Levered Free Cash Flow (ttm)
-60.77M
Research Analysis: FATE
View MoreResearch Reports: FATE
View MoreDaily – Vickers Top Buyers & Sellers for 01/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/13/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.